$28.82
-0.23(-0.77%)
Mkt Cap $1.4B
$7.57
$51.84
52-Week Range
At a Glance
AI-generatedMaze Therapeutics, Inc.
8-K
Maze Therapeutics reported fourth quarter and full year 2025 financial results with $360.0 million in cash supporting operations into 2028, announced positive Phase 2 HORIZON topline data for MZE829 showing 35.6% mean uACR reduction in broad AMKD patients, and appointed Neil Kumar as a Class I director effective March 27, 2026. These disclosures provide clinical proof-of-concept, financial visibility, and strengthened board expertise.$1.4B
Market Cap
—
Revenue
-$133M
Net Income
Employees125
Fundamentals
How The Business Makes Money
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001842295
ISINUS5787841007
CUSIP578784100
Phone650 850 5070
Address171 Oyster Point Blvd, South San Francisco, CA, 94080, US
SEC EDGAR